menu search

MDGL / Madrigal NASH Data Is Promising, Next Study Is Key For Success

Madrigal NASH Data Is Promising, Next Study Is Key For Success
Positive results achieved from the phase 3 MAESTRO-NAFLD-1 study using resmetirom to treat patients with NASH. Nearly half of patients in 100 mg dose arm achieved 50% reduction liver fat. Key study will be MAESTRO-NASH, which will have liver biopsy data. Results for this study expected later in 2022. Read More
Posted: Feb 1 2022, 13:56
Author Name: Seeking Alpha
Views: 111246

MDGL News  

Madrigal (MDGL) to Raise Capital Via Public Offering of $500M

By Zacks Investment Research
October 2, 2023

Madrigal (MDGL) to Raise Capital Via Public Offering of $500M

Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparati more_horizontal

Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.

By The Motley Fool
September 27, 2023

Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.

Analysts have high hopes for Madrigal Pharmaceuticals over the coming year. Its drug resmetirom seems effective for a liver disease, non-alcoholic ste more_horizontal

Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA

By Zacks Investment Research
September 14, 2023

Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA

Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States. more_horizontal

Madrigal Pharmaceuticals shares fall after new CEO named

By Market Watch
September 11, 2023

Madrigal Pharmaceuticals shares fall after new CEO named

Shares of Madrigal Pharmaceuticals Inc. MDGL, +2.91% fell more than 7% premarket on Monday after the company appointed Bill Sibold, a former Sanofi SN more_horizontal

Madrigal's Resmetirom Nears Commercialization Despite Market Concerns

By Seeking Alpha
August 20, 2023

Madrigal's Resmetirom Nears Commercialization Despite Market Concerns

Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Mad more_horizontal

Madrigal Pharmaceuticals' stock up 5% as company starts rolling submission for FDA approval of NASH treatment

By Market Watch
June 30, 2023

Madrigal Pharmaceuticals' stock up 5% as company starts rolling submission for FDA approval of NASH treatment

Madrigal Pharmaceuticals Inc.'s stock MDGL, +5.00% rose 5% Friday after the company said it has started a rolling submission of a New Drug Application more_horizontal

Madrigal: Setting The Pace In The NASH Market (Rating Upgrade)

By Seeking Alpha
May 30, 2023

Madrigal: Setting The Pace In The NASH Market (Rating Upgrade)

Madrigal Pharmaceuticals' drug, resmetirom, for non-alcoholic fatty liver diseases, received FDA's Breakthrough Therapy designation. The company is no more_horizontal

Why Madrigal Pharmaceuticals Stock Is Marching Higher Today

By The Motley Fool
May 24, 2023

Why Madrigal Pharmaceuticals Stock Is Marching Higher Today

The shares are continuing a yearlong winning streak today. This latest uptick appears to be the result of two tailwinds. more_horizontal


Search within

Pages Search Results: